NK Immuno T

Developing Precision Approaches to ALS

NK Immuno T is a biotechnology company advancing a biomarker-guided therapeutic program for amyotrophic lateral sclerosis.

Our goal is to translate insights into immune dysregulation into a more targeted approach to treatment development.

ALS Program Preclinical DevelopmentConceptual imagery · Not experimental data

What If a Clearer Picture
of Immunity Could Reveal
a New Way Forward in ALS?

We are investigating how differences in immune function may inform patient selection and therapeutic development.

Look Closer
See the Signals

Conceptual visualization of Natural Killer and cytotoxic CD8-positive T cellsNK cellsCD8+ T cells
Two immune populations under investigationConceptual visualization

Immune Dysregulation

Research into immune-cell activity and inflammatory signaling informs our therapeutic hypothesis in ALS.

Biomarker Strategy

Exploratory immune and genomic findings may help identify a biologically defined patient subgroup. This strategy requires validation.

Therapeutic Approach

Our investigational combination aims to address complementary inflammatory pathways while supporting cellular redox balance.

Precision is a Process

A biomarker-guided investigational approach in preclinical development.

Immune Dysregulation

Research into immune-cell activity and inflammatory signaling informs our therapeutic hypothesis in ALS.

Biomarker Strategy

Exploratory immune and genomic findings may help identify a biologically defined patient subgroup. This strategy requires validation.

Therapeutic Approach

Our investigational combination aims to address complementary inflammatory pathways while supporting cellular redox balance.

Plan Translation

Develop dose, exposure and safety study plans. Use the findings to inform a future regulatory and clinical development strategy.

Our program builds on technology originating at UCLA and research into immune dysregulation in ALS.

The Evidence Guiding Our Next Steps

Progress will depend on predefined evidence milestones.

  1. Validate Biomarkers

    Test exploratory signatures in independent, clinically characterized ALS samples using predefined assay criteria.

  2. Evaluate the Combination

    Compare the investigational combination with individual components and simpler regimens. Assess biological response alongside functional outcomes.

  3. Plan Translation

    Develop dose, exposure and safety study plans. Use the findings to inform a future regulatory and clinical development strategy.

Clinical safety and efficacy have not been established. Further studies are needed to inform future clinical development.

Conceptual visualization of natural killer and cytotoxic CD8-positive T cellsConceptual imagery

Shared Genetics
Different Outcomes

A longitudinal twin study helped frame questions about immune function in ALS. Researchers followed a person living with ALS and his unaffected identical twin, examining immune-cell populations and activity over time.

The observed differences helped generate hypotheses about immune dysregulation that inform continuing research.

Explore the published study One case can generate a research question. Larger studies are needed to establish how broadly the findings apply.

Publications

Peer-reviewed research and a recent preprint inform the program’s focus on immune dysregulation, cytotoxic immune effectors and biomarker-guided therapeutic strategies in ALS.

Leadership Advancing Our ALS Mission

Our team brings together scientists, inventors and healthcare executives with expertise in ALS, neurodegenerative diseases, immune biology and biotechnology commercialization.

Combining published research with experience in biomarker development and healthcare innovation, we are committed to advancing a biomarker-guided therapeutic approach for ALS and improving the lives of patients and families.

Kevin Combs

Kevin Combs

Chief Executive Officer and Chairman

Kevin Combs serves as Chief Executive Officer and Chairman of NK Immuno T.

Read Bio
Tom Calcagnini

Tom Calcagnini

Chief Financial Officer

Tom Calcagnini serves as Chief Financial Officer of NK Immuno T.

Read Bio
Dr. Tapan K. Khan

Dr. Tapan K. Khan

Chief Operating Officer

A biotechnology entrepreneur with more than 20 years of experience, Dr. Khan leads collaborations, funding initiatives, product development and regulatory affairs.

Read Bio
Dr. Kawaljit Kaur

Dr. Kawaljit Kaur

Chief Scientific Officer and Director

Dr. Kaur leads ALS research strategy, biomarker development and preclinical planning, drawing on expertise in immune regulation and translational medicine.

Read Bio
Robert Zell Seach

Robert “Zell” Seach

Founder, Secretary and Director

Zell brings pharmaceutical-industry and executive leadership experience in business development, strategic planning and organizational growth.

Read Bio
Mark Zilner

Mark Zilner, RPh.

Treasurer and Director

A pharmacist and healthcare entrepreneur with more than 35 years of experience, Mark brings expertise in pharmacy operations, financial oversight and corporate management.

Read Bio

Board of Directors

  • Kevin CombsChairman
  • Robert “Zell” SeachDirector
  • Mark Zilner, RPh.Director
  • Dr. Kawaljit KaurDirector

Let’s Explore
What Comes Next

For translational researchers, clinical collaborators, strategic partners and life-sciences investors.

info@NKImmunoT.com